🖼

Extended Data Fig. 9: Implications of HRD signature on CDK4/6i PFS in g BRCA2 WT breast cancers. HRD ...

active
paper figure Created: 2026-04-27T04:55:50 By: paper_figures_pipeline Quality: 50% 🔗 External ID: paper-fig-51fd0021-0cc8-4669-b21b-53650e
Extended Data Fig. 9: Implications of HRD signature on CDK4/6i PFS in g BRCA2  WT breast cancers. HRD ...
Extended Data Fig. 9Figure 12
Implications of HRD signature on CDK4/6i PFS in g BRCA2 WT breast cancers. HRD inference was performed with an orthogonal method (HRD-IMPACT, see Methods ). This included calculation of large state transitions (LST), telomeric allelic imbalance (TAI) and LOH from samples that passed purity and ASCN imputation QC metrics. The HR was derived using a Cox proportional hazard model ( P from two-sided Wald test). Among g BRCA2 WT patients, HRD was associated with a significantly shorter PFS (HR = 1.78, 95% CI: 1.27 – 2.48, P  = 0.00075).
📄 Parent paper
Metadata
doi10.1038/s41586-026-10197-0
pmcidPMC13083263
_origin{'url': 'https://www.ebi.ac.uk/europepmc/articles/PMC13083263/bin/41586_2026_10197_Fig13_ESM.jpg', 'type': 'external', 'tracked_at': '2026-04-27T11:55:50.170495'}
captionImplications of HRD signature on CDK4/6i PFS in g BRCA2 WT breast cancers. HRD inference was performed with an orthogonal method (HRD-IMPACT, see Methods ). This included calculation of large state
paper_id51fd0021-0cc8-4669-b21b-53650ed26d0f
image_urlhttps://www.ebi.ac.uk/europepmc/articles/PMC13083263/bin/41586_2026_10197_Fig13_ESM.jpg
image_path
description
figure_labelExtended Data Fig. 9
figure_number12
_schema_version1
source_strategypmc_api
entities_mentioned
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
View full evidence profile →
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.